Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease

2018 ◽  
Vol 38 (12) ◽  
pp. 2137-2148 ◽  
Author(s):  
Manoj Kumar ◽  
Suman L. Nayak ◽  
Ekta Gupta ◽  
Ashish Kataria ◽  
Shiv K. Sarin
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Direct Acting Antivirals ◽  
Direct Acting

Outcome of Direct Acting Antiviral Drugs (DAADs) for Hepatitis C Virus (HCV) in the Setting of Chronic Kidney Disease (CKD) in Upper Egypt

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Ahmed Abd El Monem Hassan ◽  
Iman Ibrahim Sarhan ◽  
Mostafa Abd Elnasier Abd El Gawad ◽  
Mohamed Mostafa Ali
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Hcv Infection ◽  
Fever Hospital ◽  
Direct Acting Antiviral ◽  
Significant Difference ◽  
Direct Acting

Abstract Background The frequency of hepatitis C virus (HCV) infection remains high in patients with chronic kidney disease (CKD) and plays a detrimental role in mortality in this population, Patients on maintenance dialysis remain at risk of acquiring hepatitis C virus (HCV) infection and the prevalence of anti-HCV seropositive patients undergoing long-term hemodialysis is significantly greater than in those with normal kidney function. Aim and objectives the aim of the study was to assess outcomes (efficacy, side effects, and possible complications) of DAADs for HCV in presence of CKD, Subjects and methods this was retrospective cohort study that was conducted at Aswan Fever Hospital and Luxor fever hospital for anti HCV therapy between Jan 2018 and July 2018 including 60 patients with all stages of CKD whom receiving DAADs were be recruited from both Aswan fever hospital and Luxor fever hospital, Results the results revealed that Patient’s PC (%) in patients from Aswan was ranged between 61-100 with mean±S.D. 83.09±9.258 while in patients from Luxor was ranged between 66-100 with mean±S.D. 84.95±6.764. There was no statistically significant difference between groups where P = 0.458, Patient’s HCV PCR in patients from Aswan at baseline show that all patients were positive while after 3 months 27(90%) were negative and 3(10%) were positive and after 6months all patients were negative while in patients from Luxor all patients were positive while after 3 months 28(93.3%) were negative and 2(6.7%) were positive and after 6 months all patients were negative. There was no statistically significant difference between groups Conclusion Treatment with newer DAAs is effective and safe for the treatment of HCV-infected chronic kidney disease patients,

scholarly journals A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease

2015 ◽  
pp. gfv361 ◽  
Author(s):  
Anna Maruyama ◽  
Nilufar Partovi ◽  
Eric M. Yoshida ◽  
Siegfried R. Erb ◽  
Vladimir Marquez Azalgara ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Direct Acting Antivirals ◽  
Advanced Chronic Kidney Disease ◽  
Direct Acting

Is it time to accept kidney transplants from donors who are hepatitis C positive?

2019 ◽  
Vol 4 (5) ◽  
pp. 266-268
Author(s):  
Michael Stephens
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Chronic Hepatitis C ◽  
Health It ◽  
Direct Acting Antivirals ◽  
Kidney Transplants ◽  
Hepatitis C Infection ◽  
Direct Acting

Is it time to accept kidney transplants from donors who are hepatitis C positive for recipients who are hepatitis C negative? With the introduction of highly effective direct-acting antivirals that are also safe to use in chronic kidney disease, chronic hepatitis C infection is no longer the risk to health it once was.

Sign in / Sign up

Export Citation Format

Share Document